z-logo
Premium
Role of transient receptor potential vanilloid‐1 (TRPV 1 ) and cannabinoid CB 1 receptors in paracetamol induced antinociception and hypothermia in mice
Author(s) -
Hamza May
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.1125.11
Subject(s) - pharmacology , chemistry , trpv , cannabinoid receptor , am251 , nociception , hypothermia , cannabinoid , agonist , capsazepine , analgesic , antagonist , receptor , trpv1 , anesthesia , transient receptor potential channel , medicine , biochemistry
Paracetamol is one of the most popular and widely used analgesic antipyretics; however, its mode of action has not been clear. It was recently shown that paracetamol is metabolized in the brain and the spinal cord to form the potent TRPV 1 agonist N‐acylphenolamine (AM‐404). AM‐404 is also an inhibitor of the cellular uptake of the endogenous cannabinoid, anandamide. This study was designed to study the contribution of TRPV 1 and CB 1 receptors in the antinociceptive and hypothermic effects of paracetamol in mice. Capsazepine, a TRPV 1 antagonist, significantly reversed the antinociceptive effect of paracetamol in the formalin test, when administered i.p. at a dose of 10 mg/kg. A higher dose (30 mg/kg), however, failed to reverse the paracetamol induced antinociceptive effect. In contrast, the higher dose partially blocked paracetamol induced hypothermia but not the lower dose. Furthermore, AM‐251, a cannabinoid CB 1 receptor antagonist, when administered i.p. at a dose of 10 mg/kg, reversed the antinociceptive effect of paracetamol in the formalin test and blocked paracetamol induced hypothermia after 2 hours of paracetamol injection. In conclusion, both TRPV 1 and CB 1 receptors are involved in paracetamol induced antinociception in mice. Hypothermia, however, might involve other mediators and further studies are needed to investigate this point.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here